Session: FP18-Diabetes: Glycemia & Insulin Sensitivity
Room 304 (Moscone Center)
Poster Board SUN-782
Methods: 19 men (mean±SEM age 28.6±2.0years, BMI 26.0±0.8kg/m2) with at least 6 months’ history (5.1±0.9years) of lifestyle driven, restricted sleep during the working week (373±6.6 min/night) with regular weekend ‘catch up’ sleep (weekend sleep extension 37.4±2.3%) completed an in-laboratory, randomised, cross-over study comprising 2 of 3 conditions, stratified by age. Conditions were 3 weekend nights of either: 10 hours, 6 hours or 10 hours time-in-bed with slow wave sleep suppression using acoustic stimuli. Reported sleep was verified at screening and before each laboratory visit by two weeks of actigraphy. Insulin sensitivity was measured on the fourth morning by minimal modelling from 19 samples drawn during a 2 hour oral glucose tolerance test. Daily fasting blood samples were taken for glucose, insulin, c-peptide; HOMA-IR, HOMA-B and QUICKI were calculated. Food intake was identical for each individual during each study visit.
Results: Insulin sensitivity improved (mean difference 8.57 x 104 min-1 (µU/ml)-1, 95% CI 1.1 to 16.1 x104, p=0.03) following 3 nights of sleep extension compared to persisting sleep restriction. Fasting insulin (-1.37iu/ml, -2.4 to -0.3, p=0.01), c-peptide (-95.8pmol/L, -144.8 to -46.8, p=0.0003), HOMA-IR (-0.31,-0.56 to -0.05, p=0.02) and HOMA-B (-18.6, -29.5 to -7.6, p=0.002) decreased, while QUICKI (0.01, 0.003 to 0.02, p=0.01) increased with sleep extension. Slow wave sleep suppression reduced SWS quantity by 23% (- 12.6min, -23.4 to -1.8, p=0.02), predominantly on night 1, and NREM delta power by power spectral analysis by 10% (-41.7 µV2, -69.3 to -13.9, p=0.005), without altering total sleep time or fragmentation, but this did not alter insulin sensitivity in this sleep deprived cohort.
Conclusion: In men with chronic, intermittent sleep restriction, 3 nights of ‘catch-up’ sleep improved insulin sensitivity. Sleep extension could prevent development of insulin resistance and diabetes mellitus.
Nothing to Disclose: RK, CMH, KM, GCD II, JP, PYL
*Please take note of The Endocrine Society's News Embargo Policy at http://www.endo-society.org/endo2013/media.cfm
See more of: Abstracts - Orals, Featured Poster Presentations, and Posters